{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:45:45Z","timestamp":1793339145348,"version":"4.5.0"},"reference-count":119,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hydroxychloroquine is one of the oldest disease-modifying anti-rheumatic drugs in clinical use. The drug interferes with lysosomal activity and antigen presentation, inhibits autophagy, and decreases transcription of pro-inflammatory cytokines. Owing to its immunomodulatory, anti-inflammatory, anti-thrombotic effect, hydroxychloroquine has been an integral part of therapy for systemic lupus erythematosus and lupus nephritis for several decades. The therapeutic versatility of hydroxychloroquine has led to repurposing it for other clinical conditions, with recent studies showing reduction in proteinuria in IgA nephropathy. Research is also underway to investigate the efficacy of hydroxychloroquine in primary membranous nephropathy, Alport\u2019s syndrome, systemic vasculitis, anti-GBM disease, acute kidney injury and for cardiovascular risk reduction in chronic kidney disease. Hydroxychloroquine is well-tolerated, inexpensive, and widely available and therefore, should its indications expand in the future, it would certainly be welcomed. However, clinicians should be aware of the risk of irreversible and progressive retinal toxicity and rarely, cardiomyopathy. Monitoring hydroxychloroquine levels in blood appears to be a promising tool to evaluate compliance, individualize the dose and reduce the risk of retinal toxicity, although this is not yet standard clinical practice. In this review, we discuss the existing knowledge regarding the mechanism of action of hydroxychloroquine, its utility in lupus nephritis and other kidney diseases, the main\u00a0adverse effects and the evidence gaps that need to be addressed in future research.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Created with Biorender.com. HCQ, hydroxychloroquine; GBM, glomerular basement membrane; mDC, myeloid dendritic cell; MHC, major histocompatibility complex; TLR, toll-like receptor<\/jats:p>","DOI":"10.1007\/s40620-023-01733-6","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T05:02:27Z","timestamp":1690952547000},"page":"2191-2208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Hydroxychloroquine in nephrology: current status and future directions"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5061-739X","authenticated-orcid":false,"given":"Indu Ramachandra","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9877-3324","authenticated-orcid":false,"given":"Ashwija","family":"Kolakemar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas Vinayak","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra Attur","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar Prasad","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharshan","family":"Rangaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan Varadanayakanahalli","family":"Bhojaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"1733_CR1","first-page":"9","volume":"44","author":"H Permin","year":"2016","unstructured":"Permin H, Norn S, Kruse E, Kruse PR (2016) On the history of Cinchona bark in the treatment of Malaria. Dan Medicinhist Arbog 44:9\u201330","journal-title":"Dan Medicinhist Arbog"},{"key":"1733_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1475-2875-10-144","volume":"10","author":"J Achan","year":"2011","unstructured":"Achan J, Talisuna AO, Erhart A et al (2011) Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J 10:144. https:\/\/doi.org\/10.1186\/1475-2875-10-144","journal-title":"Malar J"},{"key":"1733_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","volume":"23","author":"KD Rainsford","year":"2015","unstructured":"Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF (2015) Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23:231\u2013269. https:\/\/doi.org\/10.1007\/s10787-015-0239-y","journal-title":"Inflammopharmacology"},{"key":"1733_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K et al (2020) 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA\u2013EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79:713\u2013723. https:\/\/doi.org\/10.1136\/annrheumdis-2020-216924","journal-title":"Ann Rheum Dis"},{"key":"1733_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J et al (2021) KDIGO 2021 Clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"1733_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211073001","author":"A Dima","year":"2022","unstructured":"Dima A, Jurcut C, Chasset F et al (2022) Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720X211073001","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1733_CR7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","volume":"27","author":"S Tett","year":"1989","unstructured":"Tett S, Cutler D, Day R, Brown K (1989) Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 27:771\u2013779. https:\/\/doi.org\/10.1111\/j.1365-2125.1989.tb03439.x","journal-title":"Br J Clin Pharmacol"},{"key":"1733_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16:155\u2013166. https:\/\/doi.org\/10.1038\/s41584-020-0372-x","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 1","key":"1733_CR9","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1177\/0961203396005001041","volume":"5","author":"DE Furst","year":"1996","unstructured":"Furst DE (1996) Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 5(Suppl 1):S11\u2013S15","journal-title":"Lupus"},{"key":"1733_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/978-3-0348-9160-8_13","volume":"24","author":"DJ Cutler","year":"1988","unstructured":"Cutler DJ, MacIntyre AC, Tett SE (1988) Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials. Agents Actions Suppl 24:142\u2013157. https:\/\/doi.org\/10.1007\/978-3-0348-9160-8_13","journal-title":"Agents Actions Suppl"},{"key":"1733_CR11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2174\/1389200221999201208211537","volume":"21","author":"S Rendic","year":"2020","unstructured":"Rendic S, Guengerich FP (2020) Metabolism and interactions of chloroquine and hydroxychloroquine with human cytochrome P450 enzymes and drug transporters. Curr Drug Metab 21:1127\u20131135. https:\/\/doi.org\/10.2174\/1389200221999201208211537","journal-title":"Curr Drug Metab"},{"key":"1733_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1529-8019.2007.00131.x","volume":"20","author":"S Kalia","year":"2007","unstructured":"Kalia S, Dutz JP (2007) New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 20:160\u2013174. https:\/\/doi.org\/10.1111\/j.1529-8019.2007.00131.x","journal-title":"Dermatol Ther"},{"key":"1733_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.kint.2022.10.029","volume":"103","author":"F Fakhouri","year":"2023","unstructured":"Fakhouri F, Schwotzer N, Cabiddu G et al (2023) Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. Kidney Int 103:264\u2013281. https:\/\/doi.org\/10.1016\/j.kint.2022.10.029","journal-title":"Kidney Int"},{"key":"1733_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0049-0172(10)80012-5","volume":"23","author":"RI Fox","year":"1993","unstructured":"Fox RI (1993) Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 23:82\u201391. https:\/\/doi.org\/10.1016\/S0049-0172(10)80012-5","journal-title":"Semin Arthritis Rheum"},{"key":"1733_CR15","doi-asserted-by":"publisher","first-page":"25154","DOI":"10.3390\/ijms161025154","volume":"16","author":"L Wang","year":"2015","unstructured":"Wang L, Law HKW (2015) The role of autophagy in lupus nephritis. Int J Mol Sci 16:25154\u201325167. https:\/\/doi.org\/10.3390\/ijms161025154","journal-title":"Int J Mol Sci"},{"key":"1733_CR16","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","volume":"14","author":"M Mauthe","year":"2018","unstructured":"Mauthe M, Orhon I, Rocchi C et al (2018) Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 14:1435\u20131455. https:\/\/doi.org\/10.1080\/15548627.2018.1474314","journal-title":"Autophagy"},{"key":"1733_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/5071687","volume":"2019","author":"X Ye","year":"2019","unstructured":"Ye X, Zhou X, Zhang H (2019) Autophagy in immune-related renal disease. J Immunol Res 2019:1\u201310. https:\/\/doi.org\/10.1155\/2019\/5071687","journal-title":"J Immunol Res"},{"key":"1733_CR18","doi-asserted-by":"publisher","first-page":"103132","DOI":"10.1016\/j.autrev.2022.103132","volume":"21","author":"MA Podest\u00e0","year":"2022","unstructured":"Podest\u00e0 MA, Faravelli I, Ponticelli C (2022) Autophagy in lupus nephritis: a delicate balance between regulation and disease. Autoimmun Rev 21:103132. https:\/\/doi.org\/10.1016\/j.autrev.2022.103132","journal-title":"Autoimmun Rev"},{"key":"1733_CR19","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/aps.2015.91","volume":"36","author":"Y Wu","year":"2015","unstructured":"Wu Y, Tang W, Zuo J (2015) Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol Sin 36:1395\u20131407. https:\/\/doi.org\/10.1038\/aps.2015.91","journal-title":"Acta Pharmacol Sin"},{"key":"1733_CR20","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","volume":"186","author":"A Ku\u017enik","year":"2011","unstructured":"Ku\u017enik A, Ben\u010dina M, \u0160vajger U et al (2011) Mechanism of endosomal TLR Inhibition by antimalarial drugs and imidazoquinolines. J Immunol 186:4794\u20134804. https:\/\/doi.org\/10.4049\/jimmunol.1000702","journal-title":"J Immunol"},{"key":"1733_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/rheumatology\/kei282","volume":"45","author":"C-H Jang","year":"2006","unstructured":"Jang C-H, Choi J-H, Byun M-S, Jue D-M (2006) Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes\/macrophages by different modes. Rheumatology (Oxford) 45:703\u2013710. https:\/\/doi.org\/10.1093\/rheumatology\/kei282","journal-title":"Rheumatology (Oxford)"},{"key":"1733_CR22","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/art.40559","volume":"70","author":"J An","year":"2018","unstructured":"An J, Woodward JJ, Lai W et al (2018) Inhibition of cyclic GMP-AMP synthase using a novel antimalarial drug derivative in Trex1 -deficient mice. Arthritis Rheumatol 70:1807\u20131819. https:\/\/doi.org\/10.1002\/art.40559","journal-title":"Arthritis Rheumatol"},{"key":"1733_CR23","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.4049\/jimmunol.1402793","volume":"194","author":"J An","year":"2015","unstructured":"An J, Woodward JJ, Sasaki T et al (2015) Cutting edge: antimalarial drugs inhibit IFN-\u03b2 production through blockade of cyclic GMP-AMP synthase-DNA interaction. J Immunol 194:4089\u20134093. https:\/\/doi.org\/10.4049\/jimmunol.1402793","journal-title":"J Immunol"},{"key":"1733_CR24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1136\/annrheumdis-2016-210012","volume":"76","author":"N M\u00fcller-Calleja","year":"2017","unstructured":"M\u00fcller-Calleja N, Manukyan D, Canisius A et al (2017) Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. Ann Rheum Dis 76:891\u2013897. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210012","journal-title":"Ann Rheum Dis"},{"key":"1733_CR25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1177\/0961203312437270","volume":"21","author":"R Willis","year":"2012","unstructured":"Willis R, Seif A, McGwin G et al (2012) Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 21:830\u2013835. https:\/\/doi.org\/10.1177\/0961203312437270","journal-title":"Lupus"},{"key":"1733_CR26","doi-asserted-by":"publisher","first-page":"766","DOI":"10.6061\/clinics\/2013(06)07","volume":"68","author":"JC da Silva","year":"2013","unstructured":"da Silva JC, Mariz HA, da Rocha LF et al (2013) Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (Sao Paulo) 68:766\u2013771. https:\/\/doi.org\/10.6061\/clinics\/2013(06)07","journal-title":"Clinics (Sao Paulo)"},{"key":"1733_CR27","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1182\/blood.V95.11.3460","volume":"95","author":"FD Goldman","year":"2000","unstructured":"Goldman FD, Gilman AL, Hollenback C et al (2000) Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 95:3460\u20133466","journal-title":"Blood"},{"key":"1733_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2249.2006.03070.x","volume":"144","author":"W-U Kim","year":"2006","unstructured":"Kim W-U, Yoo S-A, Min S-Y et al (2006) Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. Clin Exp Immunol 144:503\u2013511. https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03070.x","journal-title":"Clin Exp Immunol"},{"key":"1733_CR29","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","volume":"112","author":"JH Rand","year":"2008","unstructured":"Rand JH, Wu X-X, Quinn AS et al (2008) Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 112:1687\u20131695. https:\/\/doi.org\/10.1182\/blood-2008-03-144204","journal-title":"Blood"},{"key":"1733_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0306-3623(97)00269-3","volume":"30","author":"J Bondeson","year":"1998","unstructured":"Bondeson J, Sundler R (1998) Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin l\u03b2 and tumor necrosis factor \u03b1 in macrophages: implications for their mode of action in rheumatoid arthritis. Gen Pharmacol 30:357\u2013366. https:\/\/doi.org\/10.1016\/S0306-3623(97)00269-3","journal-title":"Gen Pharmacol"},{"key":"1733_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1365-3083.2006.01737.x","volume":"63","author":"E Toubi","year":"2006","unstructured":"Toubi E, Kessel A, Rosner I et al (2006) The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand J Immunol 63:299\u2013303. https:\/\/doi.org\/10.1111\/j.1365-3083.2006.01737.x","journal-title":"Scand J Immunol"},{"key":"1733_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/0961203309356455","volume":"19","author":"A Lesiak","year":"2010","unstructured":"Lesiak A, Narbutt J, Sysa-Jedrzejowska A et al (2010) Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus 19:683\u2013688. https:\/\/doi.org\/10.1177\/0961203309356455","journal-title":"Lupus"},{"key":"1733_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"H-J Anders","year":"2020","unstructured":"Anders H-J, Saxena R, Zhao M et al (2020) Lupus nephritis. Nat Rev Dis Primers 6:7. https:\/\/doi.org\/10.1038\/s41572-019-0141-9","journal-title":"Nat Rev Dis Primers"},{"key":"1733_CR34","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1177\/0961203319847275","volume":"28","author":"SE Reppe Moe","year":"2019","unstructured":"Reppe Moe SE, Molberg SEH, Lerang K (2019) Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort. Lupus 28:818\u2013825. https:\/\/doi.org\/10.1177\/0961203319847275","journal-title":"Lupus"},{"key":"1733_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0889-857X(21)00232-5","volume":"20","author":"J Golbus","year":"1994","unstructured":"Golbus J, McCune WJ (1994) Lupus nephritis. Classification, prognosis, immunopathogenesis, and treatment. Rheum Dis Clin North Am 20:213\u2013242","journal-title":"Rheum Dis Clin North Am"},{"key":"1733_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.autrev.2003.11.005","volume":"3","author":"AG Uribe","year":"2004","unstructured":"Uribe AG, McGwin G, Reveille JD, Alarc\u00f3n GS (2004) What have we learned from a 10-year experience with the lumina (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading? Autoimmun Rev 3:321\u2013329. https:\/\/doi.org\/10.1016\/j.autrev.2003.11.005","journal-title":"Autoimmun Rev"},{"key":"1733_CR37","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/art.21039","volume":"52","author":"BJ Fessler","year":"2005","unstructured":"Fessler BJ, Alarc\u00f3n GS, McGwin G et al (2005) Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52:1473\u20131480. https:\/\/doi.org\/10.1002\/art.21039","journal-title":"Arthritis Rheum"},{"key":"1733_CR38","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/art.24538","volume":"61","author":"GJ Pons-Estel","year":"2009","unstructured":"Pons-Estel GJ, Alarc\u00f3n GS, McGwin G et al (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 61:830\u2013839. https:\/\/doi.org\/10.1002\/art.24538","journal-title":"Arthritis Rheum"},{"key":"1733_CR39","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1191\/0961203306lu2313oa","volume":"15","author":"N Kasitanon","year":"2006","unstructured":"Kasitanon N, Fine DM, Haas M et al (2006) Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15:366\u2013370. https:\/\/doi.org\/10.1191\/0961203306lu2313oa","journal-title":"Lupus"},{"key":"1733_CR40","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1007\/s10067-016-3366-y","volume":"35","author":"JM Mej\u00eda-Vilet","year":"2016","unstructured":"Mej\u00eda-Vilet JM, C\u00f3rdova-S\u00e1nchez BM, Uribe-Uribe NO, Correa-Rotter R (2016) Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population. Clin Rheumatol 35:2219\u20132227. https:\/\/doi.org\/10.1007\/s10067-016-3366-y","journal-title":"Clin Rheumatol"},{"key":"1733_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002891","volume":"95","author":"M Galindo-Izquierdo","year":"2016","unstructured":"Galindo-Izquierdo M, Rodriguez-Almaraz E, Pego-Reigosa JM et al (2016) Characterization of patients with lupus nephritis included in a large cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus (RELESSER). Medicine 95:e2891. https:\/\/doi.org\/10.1097\/MD.0000000000002891","journal-title":"Medicine"},{"key":"1733_CR42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/0961203319890007","volume":"29","author":"JS Lee","year":"2020","unstructured":"Lee JS, Oh JS, Kim Y-G et al (2020) Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine. Lupus 29:52\u201357. https:\/\/doi.org\/10.1177\/0961203319890007","journal-title":"Lupus"},{"key":"1733_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-04837-0","author":"FS Gheet","year":"2023","unstructured":"Gheet FS, Dawoud HE-S, El-Shahaby WA et al (2023) Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial. Eur J Pediatr. https:\/\/doi.org\/10.1007\/s00431-023-04837-0","journal-title":"Eur J Pediatr"},{"key":"1733_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1191\/096120398678919778","volume":"7","author":"E Tsakonas","year":"1998","unstructured":"Tsakonas E, Joseph L, Esdaile JM et al (1998) A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 7:80\u201385. https:\/\/doi.org\/10.1191\/096120398678919778","journal-title":"Lupus"},{"key":"1733_CR45","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0961203307086503","volume":"17","author":"A Sis\u00f3","year":"2008","unstructured":"Sis\u00f3 A, Ramos-Casals M, Bov\u00e9 A et al (2008) Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 17:281\u2013288. https:\/\/doi.org\/10.1177\/0961203307086503","journal-title":"Lupus"},{"key":"1733_CR46","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s10067-014-2527-0","volume":"33","author":"E Pokroy-Shapira","year":"2014","unstructured":"Pokroy-Shapira E, Gelernter I, Molad Y (2014) Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study. Clin Rheumatol 33:649\u2013657. https:\/\/doi.org\/10.1007\/s10067-014-2527-0","journal-title":"Clin Rheumatol"},{"key":"1733_CR47","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1093\/ndt\/gfs122","volume":"27","author":"IG Okpechi","year":"2012","unstructured":"Okpechi IG, Ayodele OE, Jones ESW et al (2012) Outcome of patients with membranous lupus nephritis in Cape Town South Africa. Nephrol Dial Transplant 27:3509\u20133515. https:\/\/doi.org\/10.1093\/ndt\/gfs122","journal-title":"Nephrol Dial Transplant"},{"key":"1733_CR48","doi-asserted-by":"publisher","first-page":"e000089","DOI":"10.1136\/lupus-2015-000089","volume":"2","author":"M Dall\u2019Era","year":"2015","unstructured":"Dall\u2019Era M, Levesque V, Solomons N et al (2015) Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med 2:e000089\u2013e000089. https:\/\/doi.org\/10.1136\/lupus-2015-000089","journal-title":"Lupus Sci Med"},{"key":"1733_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.55563\/clinexprheumatol\/ztb9sx","volume":"38","author":"OC Kwon","year":"2020","unstructured":"Kwon OC, Cho YM, Oh JS et al (2020) Factors associated with aggravation of tubulointerstitial damage on repeated biopsies in lupus nephritis patients with treatment failure. Clin Exp Rheumatol 38:239\u2013244. https:\/\/doi.org\/10.55563\/clinexprheumatol\/ztb9sx","journal-title":"Clin Exp Rheumatol"},{"key":"1733_CR50","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1136\/annrheumdis-2020-217728","volume":"81","author":"C-Y Wu","year":"2022","unstructured":"Wu C-Y, Tan M, Huang J-Y et al (2022) Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus. Ann Rheum Dis 81:e75\u2013e75. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217728","journal-title":"Ann Rheum Dis"},{"key":"1733_CR51","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/art.39070","volume":"67","author":"CH Feldman","year":"2015","unstructured":"Feldman CH, Hiraki LT, Winkelmayer WC et al (2015) Serious infections among adult medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol 67:1577\u20131585. https:\/\/doi.org\/10.1002\/art.39070","journal-title":"Arthritis Rheumatol"},{"key":"1733_CR52","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/0961203319860579","volume":"28","author":"VR Pimentel-Quiroz","year":"2019","unstructured":"Pimentel-Quiroz VR, Ugarte-Gil MF, Harvey GB et al (2019) Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. Lupus 28:1101\u20131110. https:\/\/doi.org\/10.1177\/0961203319860579","journal-title":"Lupus"},{"key":"1733_CR53","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0961203317739129","volume":"27","author":"CC Mok","year":"2018","unstructured":"Mok CC, Tse SM, Chan KL, Ho LY (2018) Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus 27:722\u2013727. https:\/\/doi.org\/10.1177\/0961203317739129","journal-title":"Lupus"},{"key":"1733_CR54","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1177\/0961203312445230","volume":"21","author":"Z Zheng","year":"2012","unstructured":"Zheng Z, Zhang L, Liu W et al (2012) Predictors of survival in Chinese patients with lupus nephritis. Lupus 21:1049\u20131056. https:\/\/doi.org\/10.1177\/0961203312445230","journal-title":"Lupus"},{"key":"1733_CR55","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1440-1797.2011.01456.x","volume":"16","author":"YB Chong","year":"2011","unstructured":"Chong YB, Yap DY, Tang CS, Chan TM (2011) Dyslipidaemia in patients with lupus nephritis. Nephrology 16:511\u2013517. https:\/\/doi.org\/10.1111\/j.1440-1797.2011.01456.x","journal-title":"Nephrology"},{"key":"1733_CR56","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jaut.2016.07.010","volume":"74","author":"G Moroni","year":"2016","unstructured":"Moroni G, Doria A, Giglio E et al (2016) Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. J Autoimmun 74:6\u201312. https:\/\/doi.org\/10.1016\/j.jaut.2016.07.010","journal-title":"J Autoimmun"},{"key":"1733_CR57","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/ki.2011.501","volume":"81","author":"JK Boyd","year":"2012","unstructured":"Boyd JK, Cheung CK, Molyneux K et al (2012) An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int 81:833\u2013843. https:\/\/doi.org\/10.1038\/ki.2011.501","journal-title":"Kidney Int"},{"key":"1733_CR58","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1681\/ASN.2007091052","volume":"19","author":"AG Gharavi","year":"2008","unstructured":"Gharavi AG, Moldoveanu Z, Wyatt RJ et al (2008) Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 19:1008\u20131014. https:\/\/doi.org\/10.1681\/ASN.2007091052","journal-title":"J Am Soc Nephrol"},{"key":"1733_CR59","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s11255-017-1574-2","volume":"49","author":"R Gao","year":"2017","unstructured":"Gao R, Wu W, Wen Y, Li X (2017) Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy. Int Urol Nephrol 49:1233\u20131241. https:\/\/doi.org\/10.1007\/s11255-017-1574-2","journal-title":"Int Urol Nephrol"},{"key":"1733_CR60","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000487330","volume":"47","author":"YZ Yang","year":"2018","unstructured":"Yang YZ, Liu LJ, Shi SF et al (2018) Effects of hydroxychloroquine on proteinuria in immunoglobulin A nephropathy. Am J Nephrol 47:145\u2013152. https:\/\/doi.org\/10.1159\/000487330","journal-title":"Am J Nephrol"},{"key":"1733_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1488-6","author":"YZ Yang","year":"2019","unstructured":"Yang YZ, Chen P, Liu LJ et al (2019) Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study. BMC Nephrol. https:\/\/doi.org\/10.1186\/s12882-019-1488-6","journal-title":"BMC Nephrol"},{"key":"1733_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-02141-9","author":"C Tang","year":"2020","unstructured":"Tang C, Lv JC, Shi SF et al (2020) Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study. BMC Nephrol. https:\/\/doi.org\/10.1186\/s12882-020-02141-9","journal-title":"BMC Nephrol"},{"key":"1733_CR63","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.ekir.2022.04.086","volume":"7","author":"S Bagchi","year":"2022","unstructured":"Bagchi S, Bhowmik D, Singh G, Agarwal SK (2022) Hydroxychloroquine reduces proteinuria in Indian patients with IgA nephropathy. Kidney Int Rep 7:1443\u20131444. https:\/\/doi.org\/10.1016\/j.ekir.2022.04.086","journal-title":"Kidney Int Rep"},{"key":"1733_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","volume":"74","author":"LJ Liu","year":"2019","unstructured":"Liu LJ, Yang Y, Shi SF et al (2019) Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 74:15\u201322. https:\/\/doi.org\/10.1053\/j.ajkd.2019.01.026","journal-title":"Am J Kidney Dis"},{"key":"1733_CR65","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s40620-021-01182-z","volume":"35","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Cheng X, Zhang Y et al (2022) Effects of hydroxychloroquine on proteinuria in membranous nephropathy. J Nephrol 35:1145\u20131157. https:\/\/doi.org\/10.1007\/s40620-021-01182-z","journal-title":"J Nephrol"},{"key":"1733_CR66","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2478\/dine-2022-0020","volume":"3","author":"X Ning","year":"2023","unstructured":"Ning X, Xu N, Chen M, Xu J (2023) Treatment with rituximab and hydroxychloroquine in a patient with membranous nephropathy and diabetic nephropathy: a case report. Diabetic Nephropathy 3:10\u201314. https:\/\/doi.org\/10.2478\/dine-2022-0020","journal-title":"Diabetic Nephropathy"},{"key":"1733_CR67","doi-asserted-by":"publisher","first-page":"10862","DOI":"10.1136\/annrheumdis-2016-eular.5464","volume":"75","author":"A Casian","year":"2016","unstructured":"Casian A, Sangle S, D\u2019Cruz D (2016) AB0531|The role of hydroxychloroquine in ANCA positive and negative vasculitis. Ann Rheum Dis 75:10862\u20131087. https:\/\/doi.org\/10.1136\/annrheumdis-2016-eular.5464","journal-title":"Ann Rheum Dis"},{"key":"1733_CR68","unstructured":"Hydroxychloroquine in ANCA Vasculitis Evaluation-Full Text View-ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04316494. Accessed 20 Feb 2023"},{"key":"1733_CR69","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/PGPM.S394290","volume":"16","author":"L Sun","year":"2023","unstructured":"Sun L, Kuang X-Y, Zhang J, Huang W-Y (2023) Hydroxychloroquine ameliorates hematuria in children with X-linked alport syndrome: retrospective case series study. Pharmgenomics Pers Med 16:145\u2013151. https:\/\/doi.org\/10.2147\/PGPM.S394290","journal-title":"Pharmgenomics Pers Med"},{"key":"1733_CR70","unstructured":"Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)-Full Text View-ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04937907. Accessed 20 Feb 2023"},{"key":"1733_CR71","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s10157-022-02285-y","volume":"27","author":"M Torigoe","year":"2023","unstructured":"Torigoe M, Obata Y, Inoue H et al (2023) Hydroxychloroquine suppresses anti-GBM nephritis via inhibition of JNK\/p38 MAPK signaling. Clin Exp Nephrol 27:110\u2013121. https:\/\/doi.org\/10.1007\/s10157-022-02285-y","journal-title":"Clin Exp Nephrol"},{"key":"1733_CR72","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41419-018-0378-3","volume":"9","author":"T-T Tang","year":"2018","unstructured":"Tang T-T, Lv L-L, Pan M-M et al (2018) Hydroxychloroquine attenuates renal ischemia\/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. Cell Death Dis 9:351. https:\/\/doi.org\/10.1038\/s41419-018-0378-3","journal-title":"Cell Death Dis"},{"key":"1733_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645100","author":"H Zheng","year":"2021","unstructured":"Zheng H, Zhang Y, He J et al (2021) Hydroxychloroquine inhibits macrophage activation and attenuates renal fibrosis after ischemia-reperfusion injury. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.645100","journal-title":"Front Immunol"},{"key":"1733_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139226","author":"AM Shukla","year":"2015","unstructured":"Shukla AM, Bose C, Karaduta OK et al (2015) Impact of hydroxychloroquine on atherosclerosis and vascular stiffness in the presence of chronic kidney disease. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0139226","journal-title":"PLoS One"},{"key":"1733_CR75","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000513567","volume":"52","author":"AM Shukla","year":"2021","unstructured":"Shukla AM, Segal MS, Pepine CJ et al (2021) Management of cardiovascular disease in kidney disease study: rationale and design. Am J Nephrol 52:36\u201344. https:\/\/doi.org\/10.1159\/000513567","journal-title":"Am J Nephrol"},{"key":"1733_CR76","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/eye.2016.298","volume":"31","author":"IH Yusuf","year":"2017","unstructured":"Yusuf IH, Sharma S, Luqmani R, Downes SM (2017) Hydroxychloroquine retinopathy. Eye 31:828\u2013845. https:\/\/doi.org\/10.1038\/eye.2016.298","journal-title":"Eye"},{"key":"1733_CR77","doi-asserted-by":"publisher","first-page":"570","DOI":"10.4103\/0301-4738.167120","volume":"63","author":"H Pandya","year":"2015","unstructured":"Pandya H, Robinson M, Mandal N, Shah V (2015) Hydroxychloroquine retinopathy: a review of imaging. Indian J Ophthalmol 63:570\u2013574. https:\/\/doi.org\/10.4103\/0301-4738.167120","journal-title":"Indian J Ophthalmol"},{"key":"1733_CR78","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1034\/j.1600-0463.2002.100606.x","volume":"110","author":"SP Sundelin","year":"2002","unstructured":"Sundelin SP, Terman A (2002) Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS 110:481\u2013489. https:\/\/doi.org\/10.1034\/j.1600-0463.2002.100606.x","journal-title":"APMIS"},{"key":"1733_CR79","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/ajcp\/aqaa253","volume":"155","author":"U Nadeem","year":"2021","unstructured":"Nadeem U, Raafey M, Kim G et al (2021) Chloroquine- and hydroxychloroquine-induced cardiomyopathy: a case report and brief literature review. Am J Clin Pathol 155:793\u2013801. https:\/\/doi.org\/10.1093\/ajcp\/aqaa253","journal-title":"Am J Clin Pathol"},{"key":"1733_CR80","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","volume":"41","author":"C Chatre","year":"2018","unstructured":"Chatre C, Roubille F, Vernhet H et al (2018) Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf 41:919\u2013931. https:\/\/doi.org\/10.1007\/s40264-018-0689-4","journal-title":"Drug Saf"},{"key":"1733_CR81","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/ehf2.12276","volume":"5","author":"H Yogasundaram","year":"2018","unstructured":"Yogasundaram H, Hung W, Paterson ID et al (2018) Chloroquine-induced cardiomyopathy: a reversible cause of heart failure. ESC Heart Fail 5:372\u2013375. https:\/\/doi.org\/10.1002\/ehf2.12276","journal-title":"ESC Heart Fail"},{"key":"1733_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.616075","author":"E Naddaf","year":"2021","unstructured":"Naddaf E, Paul P, AbouEzzeddine OF (2021) Chloroquine and hydroxychloroquine myopathy: clinical spectrum and treatment outcomes. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.616075","journal-title":"Front Neurol"},{"key":"1733_CR83","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.hrthm.2020.06.029","volume":"17","author":"M Hooks","year":"2020","unstructured":"Hooks M, Bart B, Vardeny O et al (2020) Effects of hydroxychloroquine treatment on QT interval. Heart Rhythm 17:1930\u20131935. https:\/\/doi.org\/10.1016\/j.hrthm.2020.06.029","journal-title":"Heart Rhythm"},{"key":"1733_CR84","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/14397595.2021.1879368","volume":"31","author":"T Nishiyama","year":"2021","unstructured":"Nishiyama T, Kondo Y, Tsuboi H et al (2021) QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine. Mod Rheumatol 31:1107\u20131112. https:\/\/doi.org\/10.1080\/14397595.2021.1879368","journal-title":"Mod Rheumatol"},{"key":"1733_CR85","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaa044","author":"A Pareek","year":"2020","unstructured":"Pareek A, Sharma TS, Mehta RT (2020) Hydroxychloroquine and QT prolongation: reassuring data in approved indications. Rheumatol Adv Pract. https:\/\/doi.org\/10.1093\/rap\/rkaa044","journal-title":"Rheumatol Adv Pract"},{"key":"1733_CR86","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.sapharm.2020.04.016","volume":"17","author":"A Sarayani","year":"2021","unstructured":"Sarayani A, Cicali B, Henriksen CH, Brown JD (2021) Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Res Social Adm Pharm 17:483\u2013486. https:\/\/doi.org\/10.1016\/j.sapharm.2020.04.016","journal-title":"Res Social Adm Pharm"},{"key":"1733_CR87","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.hrthm.2020.05.008","volume":"17","author":"L Jankelson","year":"2020","unstructured":"Jankelson L, Karam G, Becker ML et al (2020) QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review. Heart Rhythm 17:1472\u20131479. https:\/\/doi.org\/10.1016\/j.hrthm.2020.05.008","journal-title":"Heart Rhythm"},{"key":"1733_CR88","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-4362.1992.tb02689.x","volume":"31","author":"JD Hendrix","year":"1992","unstructured":"Hendrix JD, Greer KE (1992) Cutaneous hyperpigmentation caused by systemic drugs. Int J Dermatol 31:458\u2013466. https:\/\/doi.org\/10.1111\/j.1365-4362.1992.tb02689.x","journal-title":"Int J Dermatol"},{"key":"1733_CR89","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/01.rhu.0000260649.36417.09","volume":"13","author":"B Amichai","year":"2007","unstructured":"Amichai B, Gat A, Grunwald MH (2007) Cutaneous hyperpigmentation during therapy with hydroxychloroquine. J Clin Rheumatol 13:113. https:\/\/doi.org\/10.1097\/01.rhu.0000260649.36417.09","journal-title":"J Clin Rheumatol"},{"key":"1733_CR90","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/1529-0131(199902)42:2<357::AID-ANR19>3.0.CO;2-J","volume":"42","author":"DE Furst","year":"1999","unstructured":"Furst DE, Lindsley H, Baethge B et al (1999) Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum 42:357\u2013365. https:\/\/doi.org\/10.1002\/1529-0131(199902)42:2%3c357::AID-ANR19%3e3.0.CO;2-J","journal-title":"Arthritis Rheum"},{"key":"1733_CR91","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1177\/0961203314561667","volume":"24","author":"SM Abdel Galil","year":"2015","unstructured":"Abdel Galil SM (2015) Hydroxychloroquine-induced toxic hepatitis in a patient with systemic lupus erythematosus: a case report. Lupus 24:638\u2013640. https:\/\/doi.org\/10.1177\/0961203314561667","journal-title":"Lupus"},{"key":"1733_CR92","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.xkme.2021.01.006","volume":"3","author":"S Manabe","year":"2021","unstructured":"Manabe S, Mochizuki T, Sato M et al (2021) Lupus nephritis and hydroxychloroquine-associated zebra bodies: not just in fabry disease. Kidney Med 3:442\u2013446. https:\/\/doi.org\/10.1016\/j.xkme.2021.01.006","journal-title":"Kidney Med"},{"key":"1733_CR93","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","volume":"132","author":"RB Melles","year":"2014","unstructured":"Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453\u20131460. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.3459","journal-title":"JAMA Ophthalmol"},{"key":"1733_CR94","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/art.41683","volume":"73","author":"JT Rosenbaum","year":"2021","unstructured":"Rosenbaum JT, Costenbader KH, Desmarais J et al (2021) American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. Arthritis Rheumatol 73:908\u2013911. https:\/\/doi.org\/10.1002\/art.41683","journal-title":"Arthritis Rheumatol"},{"key":"1733_CR95","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1001\/jama.2022.13591","volume":"328","author":"AM Jorge","year":"2022","unstructured":"Jorge AM, Mancini C, Zhou B et al (2022) Hydroxychloroquine dose per ophthalmology guidelines and the risk of systemic lupus erythematosus flares. JAMA 328:1458. https:\/\/doi.org\/10.1001\/jama.2022.13591","journal-title":"JAMA"},{"key":"1733_CR96","volume-title":"The renal drug handbook","author":"A Caroline","year":"2009","unstructured":"Caroline A, Aileen D (2009) The renal drug handbook. Radcliffe Pub"},{"key":"1733_CR97","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41433-018-0136-x","volume":"32","author":"IH Yusuf","year":"2018","unstructured":"Yusuf IH, Foot B, Galloway J et al (2018) The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye 32:1168\u20131173. https:\/\/doi.org\/10.1038\/s41433-018-0136-x","journal-title":"Eye"},{"key":"1733_CR98","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/art.41121","volume":"72","author":"M Petri","year":"2020","unstructured":"Petri M, Elkhalifa M, Li J et al (2020) Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol 72:448\u2013453. https:\/\/doi.org\/10.1002\/art.41121","journal-title":"Arthritis Rheumatol"},{"key":"1733_CR99","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/acr.24155","volume":"73","author":"S Garg","year":"2021","unstructured":"Garg S, Unnithan R, Hansen KE et al (2021) Clinical significance of monitoring hydroxychloroquine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 73:707\u2013716. https:\/\/doi.org\/10.1002\/acr.24155","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1733_CR100","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1136\/ard.2006.067835","volume":"66","author":"N Costedoat-Chalumeau","year":"2007","unstructured":"Costedoat-Chalumeau N, Amoura Z, Hulot JS et al (2007) Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 66:821\u2013824. https:\/\/doi.org\/10.1136\/ard.2006.067835","journal-title":"Ann Rheum Dis"},{"key":"1733_CR101","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1080\/0886022X.2021.2000875","volume":"43","author":"G Stefan","year":"2021","unstructured":"Stefan G, Mircescu G (2021) Hydroxychloroquine in IgA nephropathy: a systematic review. Ren Fail 43:1520\u20131527. https:\/\/doi.org\/10.1080\/0886022X.2021.2000875","journal-title":"Ren Fail"},{"key":"1733_CR102","first-page":"95","volume":"32","author":"MWP Tsang-A-Sjoe","year":"2014","unstructured":"Tsang-A-Sjoe MWP, Bultink IEM, Voskuyl AE (2014) Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use. Clin Exp Rheumatol 32:95\u2013100","journal-title":"Clin Exp Rheumatol"},{"key":"1733_CR103","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/ard.2006.068676","volume":"66","author":"GS Alarc\u00f3n","year":"2007","unstructured":"Alarc\u00f3n GS, McGwin G, Bertoli AM et al (2007) Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66:1168\u20131172. https:\/\/doi.org\/10.1136\/ard.2006.068676","journal-title":"Ann Rheum Dis"},{"key":"1733_CR104","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/art.27300","volume":"62","author":"SK Shinjo","year":"2010","unstructured":"Shinjo SK, Bonf\u00e1 E, Wojdyla D et al (2010) Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 62:855\u2013862. https:\/\/doi.org\/10.1002\/art.27300","journal-title":"Arthritis Rheum"},{"key":"1733_CR105","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3899\/jrheum.150671","volume":"43","author":"LJ Herrinton","year":"2016","unstructured":"Herrinton LJ, Liu L, Goldfien R et al (2016) Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimalarials. J Rheumatol 43:1503\u20131509. https:\/\/doi.org\/10.3899\/jrheum.150671","journal-title":"J Rheumatol"},{"key":"1733_CR106","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semarthrit.2017.01.010","volume":"47","author":"\u00cd R\u00faa-Figueroa","year":"2017","unstructured":"R\u00faa-Figueroa \u00cd, L\u00f3pez-Longo J, Galindo-Izquierdo M et al (2017) Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum 47:38\u201345. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.01.010","journal-title":"Semin Arthritis Rheum"},{"key":"1733_CR107","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12879-020-4826-1","volume":"20","author":"K-J Yeo","year":"2020","unstructured":"Yeo K-J, Chen H-H, Chen Y-M et al (2020) Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study. BMC Infect Dis 20:112. https:\/\/doi.org\/10.1186\/s12879-020-4826-1","journal-title":"BMC Infect Dis"},{"key":"1733_CR108","first-page":"622","volume":"32","author":"MY Mok","year":"2005","unstructured":"Mok MY, Chan EYT, Fong DYT et al (2005) Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol 32:622\u2013628","journal-title":"J Rheumatol"},{"key":"1733_CR109","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/0961203306071872","volume":"15","author":"G Ruiz-Irastorza","year":"2006","unstructured":"Ruiz-Irastorza G, Egurbide MV, Pijoan JI et al (2006) Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15:577\u2013583. https:\/\/doi.org\/10.1177\/0961203306071872","journal-title":"Lupus"},{"key":"1733_CR110","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/art.41621","volume":"73","author":"M Petri","year":"2021","unstructured":"Petri M, Konig MF, Li J, Goldman DW (2021) Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus. Arthritis Rheumatol 73:997\u20131004. https:\/\/doi.org\/10.1002\/art.41621","journal-title":"Arthritis Rheumatol"},{"key":"1733_CR111","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/0002-9343(90)90345-E","volume":"89","author":"DJ Wallace","year":"1990","unstructured":"Wallace DJ, Metzger AL, Stecher VJ et al (1990) Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 89:322\u2013326. https:\/\/doi.org\/10.1016\/0002-9343(90)90345-E","journal-title":"Am J Med"},{"key":"1733_CR112","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00124743-199702000-00002","volume":"3","author":"A Kavanaugh","year":"1997","unstructured":"Kavanaugh A, Adams-Huet B, Jain R et al (1997) Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 3:3\u20138","journal-title":"J Clin Rheumatol"},{"key":"1733_CR113","first-page":"965","volume":"94","author":"J Meng","year":"2014","unstructured":"Meng J, Lu Y, Dong X, Liu H (2014) Long-term effects of hydroxychloroquine on metabolism of serum lipids and left ventricular structure and function in patients of systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi 94:965\u2013968","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1733_CR114","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1161\/CIRCULATIONAHA.111.089268","volume":"126","author":"PM Izmirly","year":"2012","unstructured":"Izmirly PM, Costedoat-Chalumeau N, Pisoni CN et al (2012) Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA\/Ro-antibody\u2013Associated Cardiac Manifestations of Neonatal Lupus. Circulation 126:76\u201382. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.089268","journal-title":"Circulation"},{"key":"1733_CR115","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0961203319843343","volume":"28","author":"MR Seo","year":"2019","unstructured":"Seo MR, Chae J, Kim YM et al (2019) Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus 28:722\u2013730. https:\/\/doi.org\/10.1177\/0961203319843343","journal-title":"Lupus"},{"key":"1733_CR116","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0002-9343(88)90363-4","volume":"85","author":"N Rothfield","year":"1988","unstructured":"Rothfield N (1988) Efficacy of antimalarials in systemic lupus erythematosus. Am J Med 85:53\u201356. https:\/\/doi.org\/10.1016\/0002-9343(88)90363-4","journal-title":"Am J Med"},{"key":"1733_CR117","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1177\/09612033211002269","volume":"30","author":"S Fasano","year":"2021","unstructured":"Fasano S, Coscia MA, Pierro L, Ciccia F (2021) Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study. Lupus 30:991\u2013997. https:\/\/doi.org\/10.1177\/09612033211002269","journal-title":"Lupus"},{"key":"1733_CR118","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/annrheumdis-2021-221295","volume":"81","author":"CC Almeida-Brasil","year":"2022","unstructured":"Almeida-Brasil CC, Hanly JG, Urowitz M et al (2022) Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis 81:370\u2013378. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221295","journal-title":"Ann Rheum Dis"},{"key":"1733_CR119","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/rheumatology\/keab373","volume":"61","author":"M Zen","year":"2022","unstructured":"Zen M, Fuzzi E, Loredo Martinez M et al (2022) Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. Rheumatology 61:688\u2013695. https:\/\/doi.org\/10.1093\/rheumatology\/keab373","journal-title":"Rheumatology"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01733-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-023-01733-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01733-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:52:47Z","timestamp":1777564367000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/36\/8\/2191\/8304237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":119,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["1733"],"URL":"https:\/\/doi.org\/10.1007\/s40620-023-01733-6","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]},"assertion":[{"value":"4 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}